10x Genomics Drops Patent Suit Against Parse Biosciences
The company will dismiss claims after a federal court invalidated three key cell-analysis patents, clearing a legal hurdle.
Updated on Oct. 22, 2026 in Biotech
Live Poll
Do you believe current patent invalidation processes strike the right balance between protecting and fostering innovation?
10x Genomics is ending its patent infringement lawsuit against Parse Biosciences following a court ruling that invalidated three key cell-analysis patents. The companies are currently preparing to file a stipulation to dismiss all claims with prejudice in the U.S. District Court for the District of Delaware.
Why it matters
The Federal Circuit decision limits the scope of intellectual property claims surrounding cell-analysis technology, effectively clearing the legal path for competitors. This outcome marks a significant shift in the patent landscape for single-cell research tools.
The Federal Circuit invalidated U.S. Patent Nos. 10,155,981, 10,240,197, and 10,697,013. These patents previously formed the technical basis for claims regarding cell-analysis methodology.
The players
10x Genomics
A developer of single-cell and spatial biology tools used for analyzing gene expression and cellular heterogeneity.
Parse Biosciences
A biotech firm specializing in high-throughput single-cell sequencing solutions that compete in the genomic analysis market.
The details
The legal conflict centered on whether Parse Biosciences technology infringed on proprietary cell-analysis methods protected by 10x Genomics patents. After an administrative tribunal initially moved to invalidate these specific assets, the Federal Circuit upheld the decision, finding the patents legally unenforceable. This ruling effectively removes the foundational intellectual property that 10x Genomics used to challenge the competitor.
Timeline
August 2026: The Federal Circuit upheld the invalidation of three patents.
October 21, 2026: The parties notified the District Court of their intent to dismiss.
Late October 2026: A formal dismissal stipulation will be submitted.
The Tech Race
This resolution follows a long-standing pattern of patent litigation within the single-cell sequencing sector as firms seek to secure market dominance. The invalidation of these assets marks a significant narrowing of the defensive moats protecting incumbents in the biotech research tool market.
Researchers and labs using single-cell sequencing can expect increased competition as legal barriers to entry fall. This shifts the market environment, potentially leading to more options for labs seeking diverse cell-analysis platforms.
The takeaway
The dismissal signals the end of this specific legal conflict, though the broader competition for cell-analysis dominance continues. Watch for future patent filings or market shifts as companies adjust to the loss of these key legal protections.
Further reading
For broader trends in intellectual property, visit the Biotech section.
Live Poll
Do you believe current patent invalidation processes strike the right balance between protecting and fostering innovation?
